



## Towards Precision Medicine in Gestational Diabetes Mellitus

Guest Editors:

**Prof. Dr. Huixia Yang**

Department of Obstetrics and  
Gynecology, Peking University  
First Hospital, Peking University,  
Beijing 100034, China

**Dr. Juan Juan**

Peking University First Hospital,  
Peking University, Beijing 100034,  
China


Deadline for manuscript  
submissions:

**closed (31 July 2023)**

### Message from the Guest Editors

Gestational diabetes mellitus (GDM) is one of the most common metabolic complications during pregnancy and causes a tremendous health and economic burden worldwide. The prevalence of GDM has continued to increase during the past few decades and is likely to see a further rise in the future. The public health impact of GDM is becoming more apparent, and it might lead to the development of chronic non-communicable diseases in later life for both mothers and their children. Early identification of high-risk individuals could help to take precise preventive and intervention measures to reduce the risk of GDM and adverse outcomes. Therefore, a focus on **precision medicine in gestational diabetes mellitus** is of great importance. Lifestyle interventions, including dietary and physical exercise intervention, are effective and first-line preventive strategies for GDM prevention and intervention. This Special Issue focuses on precise prevention, lifestyle intervention, as well as the prevalence of maternal and neonatal outcomes of GDM for better understanding of precision medicine in GDM.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Senior Vice President and Director, Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Professor of Medicine Chief, Section of Hematologic Malignancies, Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute, Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:**— free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Journal of Personalized Medicine*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[@JPM\\_MDPI](https://twitter.com/JPM_MDPI)